Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Arovella Therapeutics Limited (ALA.AX)
Osborne Park, WA, AU
Arovella Therapeutics Limited, an Australian biotechnology firm, is dedicated to developing therapeutic solutions for oncology and central nervous system afflictions, operating both domestically and internationally. Its pipeline features several key assets, including ZolpiMist, an oral spray formulation of zolpidem tartrate for the treatment of short-term insomnia, commercially known by brands such as Ambien or Stilnox. The company is also advancing an invariant natural killer T (iNKT) cell therapy platform specifically designed to target blood cancers. Furthermore, Arovella employs OroMist, an oro-mucosal technology enabling the delivery of various drug classes through absorption in the oral cavity via the cheeks, gums, tongue, or mouth floor, and is developing Anagrelide for cancer treatment. Beyond these, the company is engaged in creating oral sprays to address conditions like migraine headaches, motion sickness, and drug-resistant epilepsy. Arovella maintains a research collaboration agreement with Imperial College London. Established in 1999 and based in Osborne Park, Australia, the company was formerly known as Suda Pharmaceuticals Ltd before rebranding to Arovella Therapeutics Limited in October 2021.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | -1.39% | -11.25% | -13.41% | -16.47% | -23.66% | -6.58% | +39.22% | +73.17% | -83.26% | -97.84% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2025-04 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Biotechnology: +1.6%+700.0% ★ Q4'25: -100.0% (vs Q4'23)
-
EPS growth Biotechnology: +29.7%+26.9% Q4'25: +63.6% (vs Q4'23)
-
FCF margin FCF growth · Biotechnology: +16.2%-6,087.6%
-
EBIT margin Biotechnology: +0.0%-8,237.4%
-
ROIC Biotechnology: -16.1%— Q4'25: +2,941.8% (vs Q4'23)
-
Share dilution Biotechnology: -3.4%+16.6% Q4'25: +32.8% (vs Q4'23)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×0.00× Q4'25: 0.00× (vs Q4'23)
| Metric |
Jun 2015 actual |
Jun 2016 actual |
Jun 2018 actual |
Jun 2019 actual |
Jun 2020 actual |
Jun 2021 actual |
Jun 2022 actual |
Jun 2023 actual |
Jun 2025 actual |
Jun 2026 1 Rev. Ana. 1 EPS Ana. |
Jun 2027 1 Rev. Ana. 1 EPS Ana. |
Jun 2028 1 Rev. Ana. |
Jun 2029 1 Rev. Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
5.62M
est: 5.73M (-1.8%)
|
5.79M
est: 34.00M (-83.0%)
|
425.9K
est: 5.73M (-92.6%)
|
1.22M
est: 34.00M (-96.4%)
|
532.7K
est: 740.0K (-28.0%)
|
257.3K
est: 485.0K (-46.9%)
|
295.8K
est: 400.0K (-26.0%)
|
405.9K
est: 380.0K (+6.8%)
|
136.0K
est: 3.30M (-95.9%)
|
3.80M
3.80M – 3.80M
+15.2% YoY
|
6.70M
6.70M – 6.70M
+76.3% YoY
|
61.50M
61.50M – 61.50M
+817.9% YoY
|
109.30M
109.30M – 109.30M
+77.7% YoY
|
| EBITDA |
-3.70M
est: -5.73M (+35.4%)
|
-2.72M
est: -34.00M (+92.0%)
|
-6.44M
est: -5.73M (-12.5%)
|
-8.12M
est: -34.00M (+76.1%)
|
-3.40M
est: -740.0K (-360.0%)
|
-4.99M
est: -485.0K (-929.8%)
|
-7.87M
est: -400.0K (-1,868.6%)
|
-10.37M
est: -380.0K (-2,629.5%)
|
-11.10M
est: -3.30M (-236.2%)
|
-3.80M
-3.80M – -3.80M
-15.2% YoY
|
-6.70M
-6.70M – -6.70M
-76.3% YoY
|
-61.50M
-61.50M – -61.50M
-817.9% YoY
|
-109.30M
-109.30M – -109.30M
-77.7% YoY
|
| EBIT |
-3.88M
est: -5.73M (+32.3%)
|
-2.84M
est: -34.00M (+91.6%)
|
-6.60M
est: -5.73M (-15.3%)
|
-8.59M
est: -34.00M (+74.7%)
|
-4.87M
est: -740.0K (-557.5%)
|
-5.65M
est: -485.0K (-1,064.2%)
|
-8.43M
est: -400.0K (-2,006.5%)
|
-11.21M
est: -380.0K (-2,849.9%)
|
-11.20M
est: -3.30M (-239.5%)
|
-3.80M
-3.80M – -3.80M
-15.2% YoY
|
-6.70M
-6.70M – -6.70M
-76.3% YoY
|
-61.50M
-61.50M – -61.50M
-817.9% YoY
|
-109.30M
-109.30M – -109.30M
-77.7% YoY
|
| Net Income |
-3.37M
est: -66.78M (+95.0%)
|
-2.23M
|
-5.46M
est: -66.78M (+91.8%)
|
-7.80M
|
-9.94M
est: -27.89M (+64.3%)
|
-5.05M
est: -1.42B (+99.6%)
|
-8.62M
est: -10.97M (+21.4%)
|
-10.18M
est: -10.97M (+7.2%)
|
-7.51M
est: -9.87M (+24.0%)
|
-14.26M
-14.26M – -14.26M
-44.4% YoY
|
-19.75M
-19.75M – -19.75M
-38.5% YoY
|
—
— – —
+100.0% YoY
|
—
— – —
|
| SGA |
2.47M
est: 242.47M (-99.0%)
|
2.30M
est: 1.44B (-99.8%)
|
1.61M
est: 242.47M (-99.3%)
|
1.19M
est: 1.44B (-99.9%)
|
2.17M
est: 31.33M (-93.1%)
|
2.20M
est: 20.53M (-89.3%)
|
2.63M
est: 16.93M (-84.4%)
|
3.54M
est: 16.09M (-78.0%)
|
3.06M
est: 139.70M (-97.8%)
|
160.87M
160.87M – 160.87M
+15.2% YoY
|
283.64M
283.64M – 283.64M
+76.3% YoY
|
2.60B
2.60B – 2.60B
+817.9% YoY
|
4.63B
4.63B – 4.63B
+77.7% YoY
|
| EPS |
-0.06
est: -0.06 (-0.4%)
|
-0.04
|
-0.08
est: -0.06 (-35.4%)
|
-0.07
|
-0.06
est: -0.03 (-132.9%)
|
-0.02
est: -1.29 (+98.8%)
|
-0.02
est: -0.01 (-57.0%)
|
-0.01
est: -0.01 (-43.0%)
|
-0.01
est: -0.01 (+24.4%)
|
-0.01
-0.01 – -0.01
-44.4% YoY
|
-0.02
-0.02 – -0.02
-38.5% YoY
|
—
— – —
+100.0% YoY
|
—
— – —
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-28 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-27 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-26 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-25 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-22 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-21 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-20 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-19 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-18 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-15 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-14 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-13 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-12 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-11 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-08 | D+ | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-07 | D+ | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-06 | D+ | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-05 | D+ | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-04 | D+ | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-01 | D+ | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-30 | D+ | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-29 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-28 | D+ | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-27 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-24 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-23 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-22 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-21 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-20 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-17 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-16 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Michael Baker | CEO & MD | 577.2K | — |
| Nicole van der Weerden | Chief Operating Officer | 451.5K | — |
| Lachie Mallia | Company Secretary & Chief Financial Officer | — | male |
| Michelle Ferguson | Senior Director of Research & Development | — | — |
| Michelle Long | Administration Manager | — | female |
| Robson Dossa | Senior Vice President of Manufacturing & Quality | — | — |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for ALA.AX
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
